Detalhe da pesquisa
1.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
PLoS Med
; 21(3): e1004360, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502656
2.
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Clin Infect Dis
; 72(1): 50-60, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900486
3.
HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
J Virol
; 92(1)2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29021402
4.
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
J Infect Dis
; 213(12): 1946-54, 2016 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26908741
5.
Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.
J Virol
; 88(16): 9406-17, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24920809
6.
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges.
Front Immunol
; 13: 788619, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35273592
7.
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.
EBioMedicine
; 84: 104271, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179551
8.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898870
9.
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
PLoS One
; 13(4): e0194266, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29698406
10.
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
J Infect Dis
; 192(12): 2129-33, 2005 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16288378